Quick answer: Breast implant-associated anaplastic large cell lymphoma, or BIA-ALCL, is a rare cancer of the immune system that usually develops in fluid or scar tissue around a breast implant. It is not the usual form of breast cancer. Persistent swelling, a new lump or pain around an implant—often years after surgery—should be assessed promptly. These symptoms usually have other causes, but they should not be ignored. If you have implants and no symptoms, the US FDA does not recommend routine removal solely because of BIA-ALCL concern.
The term can sound frightening, especially if you have just read about a device recall. A useful first step is to separate three questions: what device you have, whether you have a new symptom, and what an experienced clinician finds. People who have breast augmentation or implant reconstruction deserve clear information about this risk without being told that every ache is lymphoma. The current evidence links BIA-ALCL more strongly with textured-surface implants than with smooth-surface implants. The filling—saline or silicone—is a separate property and is not the central distinction for this disease.
This article describes signs, investigations and decisions. It cannot assess an individual lump or swelling online. New breast symptoms also need ordinary breast and implant evaluation, because infection, rupture, scar tightening, benign fluid collections and breast tissue conditions can produce similar changes. Tell the clinician about your implant history rather than trying to name the cause yourself.
What exactly is BIA-ALCL?
BIA-ALCL is a type of non-Hodgkin lymphoma. It typically arises in the fluid or fibrous capsule that forms around an implant, rather than in breast gland tissue. The FDA's patient questions explain this location and the need for a different diagnostic and surgical plan if the condition is confirmed. Most patients are diagnosed after noticing a change around an implant that had previously settled.
It is rare, but a rare condition can still be serious. A person should not use “rare” as a reason to dismiss persistent one-sided swelling. Conversely, a new collection of fluid is not itself a cancer diagnosis. A clinical examination, appropriate imaging and testing of fluid or tissue are required. The American Society of Plastic Surgeons (ASPS) says many patients with localised disease can be treated successfully, particularly when evaluated and managed appropriately.
It is also distinct from breast implant rupture. Rupture is a tear in the implant shell; BIA-ALCL is a lymphoma associated with the tissue around some implants. They may both cause discomfort or a change in shape, so symptoms cannot reliably separate them. The imaging and laboratory questions must be made explicit when a late fluid collection or mass is present.
Which symptoms should prompt a review?
The main warning signs are persistent or increasing swelling, a mass in the breast or underarm, and pain around the implant. A fluid collection can make one breast larger or change its shape. Some patients report firmness, a rash or a new change in the capsule. These signs often appear after the original surgery has fully healed, sometimes years later. The FDA and ASPS patient information both advise evaluation rather than self-diagnosis.
Write down when the change began and whether it is getting worse. Note previous infection, trauma, rupture, revision surgery or breast cancer treatment. Bring your implant card or operation note if available, especially the manufacturer's name and whether the surface is textured. If you cannot locate the card, still book the appointment. The surgeon may be able to obtain records, and the symptom can be assessed without waiting for the exact device number.
Rapidly increasing swelling, fever, redness, a hot breast or feeling significantly unwell may indicate infection or another urgent complication. Seek prompt care. A stable but persistent new swelling or lump also needs timely review, even if it is not painful. A routine annual appointment months away is not a suitable substitute for assessing a new mass.
Why does implant texture matter?
Implant surface can be smooth or textured. Evidence reviewed by the FDA shows a higher BIA-ALCL risk with textured implants than with smooth implants. The absolute risk varies by device and available study data, and an exact personal probability cannot be calculated from an online number. The ASPS advisory gives background on textured devices and cautions that the science continues to develop.
A patient may have had more than one implant over time. Prior exposure to a textured device matters even if a smooth device is present now. Give the surgeon your full implant history where possible. Textured tissue expanders used temporarily before reconstruction may also be relevant. The FDA's guidance discusses uncertainty about the risk after a temporary expander; do not assume a short exposure means zero risk or that it means disease is likely.
One widely publicised textured implant recall created understandable concern. A recall prevents further use of the affected product; it does not automatically mean every person with that implant needs urgent removal. The FDA recall notice and FDA patient guidance distinguish unused devices from people already carrying implants. If you know you have a recalled device, discuss follow-up and symptoms with your surgeon.
What happens at the first assessment?
The clinician will ask about the change and examine the breast, implant area and nearby lymph nodes. Ultrasound is often used to look for fluid around the implant or a mass. MRI may be useful in selected cases. Imaging helps locate a problem but does not by itself make the final lymphoma diagnosis. A new lump in ordinary breast tissue may need its own breast diagnostic pathway as well.
If there is fluid or suspicious tissue, the clinician may arrange a needle sample. A pathologist checks the cells with tests appropriate for BIA-ALCL, including CD30 immunostaining when indicated. The ASPS patient brochure describes examination, ultrasound or MRI and fluid or tissue testing. Tell the imaging and pathology teams that an implant-associated condition is being considered so the sample can be handled appropriately.
Do not ask someone to simply “drain the swelling” without a plan for analysis when a late unexplained collection is present. Removing fluid may make the breast feel temporarily better while losing an opportunity to test it. Equally, a fluid collection does not automatically call for a large operation before pathology is known. The assessment should identify the cause and guide the next step.
If BIA-ALCL is diagnosed, what treatment is used?
The treatment plan depends on how far the disease extends. For disease confined to the implant area, surgery usually involves removing the implant and the surrounding capsule. A mass may need to be removed as part of an appropriate cancer operation. An oncology team may recommend further staging tests. Disease that extends beyond the capsule may require additional treatment. The FDA explains that confirmed BIA-ALCL changes the operation compared with implant removal alone.
This is why an unexplained late swelling should be investigated before an elective implant exchange. If a lymphoma is found, the team needs to plan surgery for cancer clearance rather than treat the situation as a cosmetic revision. Ask whether the surgeon has involved a breast or haematology-oncology specialist and what the pathology report shows. A specialist team can explain stage, treatment, follow-up and the evidence behind each recommendation.
Do not confuse this with advice to remove the capsule from every healthy person who has implants. More extensive capsule surgery can add risk. The reason for removing it in confirmed BIA-ALCL is specific to the disease. For someone with no symptoms or diagnosis, the decision about implant removal or exchange is individual and should include the risks of another operation.
What if you have no symptoms?
Know what is normal for you and keep routine medical follow-up. Learn whether your current or earlier implants were textured if records are available. If you do not know, request the device card or operative note without panic. The FDA does not recommend preventive removal of implants solely because of BIA-ALCL worry when there are no symptoms. That advice also applies to people affected by certain recalls, although an individual may choose a consultation for other reasons.
Continue breast cancer screening advised for your age and personal risk. BIA-ALCL is not ordinary breast cancer, and a routine mammogram is not a specific screening test for it. The ASPS FAQ says there is no established screening test for BIA-ALCL in people without symptoms. Device-integrity ultrasound or MRI for silicone rupture answers yet another question. A clinician can help you keep these forms of follow-up separate.
If you are planning an implant operation, ask the surgeon which surface type is proposed and why. Discuss the benefits, alternatives and device-specific risks, including future monitoring. You can ask for the manufacturer's written patient information and an implant card after surgery. Knowing the device details makes it easier to get appropriate advice years later.
Questions to ask the clinician
- Were my current or past implants textured, and can we confirm the device records?
- Does the swelling or mass involve fluid, the capsule, breast tissue or a lymph node?
- Should ultrasound, MRI, a fluid sample or a tissue biopsy be arranged?
- Will the sample be tested in a way that can evaluate BIA-ALCL if it is suspected?
- If the result is benign, what explains the symptom and when should it be rechecked?
- If BIA-ALCL is confirmed, which specialist team will plan surgery and follow-up?
Ask for written results and a clear follow-up appointment. “Probably nothing” without a plan is not enough for persistent unexplained swelling. You can also ask what changes should trigger an earlier call. If you are feeling anxious, tell the team; a defined investigation plan often helps more than repeatedly searching for photos of other patients' symptoms.
Frequently asked questions
Is BIA-ALCL the same as breast cancer?
No. It is a lymphoma of the immune system that usually occurs in fluid or capsule tissue around an implant, rather than in breast gland tissue. A person can still develop unrelated breast conditions, so a new symptom needs proper assessment.
Does every swollen breast after implants mean lymphoma?
No. Swelling can result from several causes. A persistent new swelling, particularly long after healing, should be assessed because the cause cannot be established by appearance alone. Imaging and sometimes testing of fluid or tissue determine the next step.
Should I remove a textured implant if I feel well?
The FDA does not recommend routine removal solely because of BIA-ALCL concern in people without symptoms. Discuss your own device history, other implant problems and preferences with a qualified surgeon before deciding on another operation.
Can a blood test screen for BIA-ALCL?
There is no established routine blood screening test for an asymptomatic implant patient. When symptoms suggest the disease, the diagnostic process usually focuses on imaging and analysis of fluid or tissue from the affected area.
Practical takeaway
BIA-ALCL is rare but needs a specific assessment when a patient develops persistent swelling, a mass or pain around an implant. Texture history helps the clinician judge risk; symptoms and test results guide action. If you have no symptoms, keep normal follow-up and do not make a rushed removal decision from a recall headline. The breast augmentation service page explains implant surgery; a personal consultation is the place to review your device records and any new change.
